Fennec Announces Hearing Loss Results at SIOP 2026
Fennec Pharmaceuticals announced the STS-J01 clinical results showing a significant reduction in cisplatin-induced ototoxicity. The trial supports the efficacy of PEDMARK® in pediatric patients.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed